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Currently, one of the main objectives of human–animal interaction research is to
demonstrate the benefits of animal assisted therapy (AAT) for specific profiles of patients
or participants. The aim of this study is to assess the effect of an AAT program as an
adjunct to a conventional 6-month psychosocial rehabilitation program for people with
schizophrenia. Our hypothesis is that the inclusion of AAT into psychosocial rehabilitation
would contribute positively to the impact of the overall program on symptomology
and quality of life, and that AAT would be a positive experience for patients. To test
these hypotheses, we compared pre-program with post-program scores for the Positive
and Negative Syndrome Scale (PANSS) and the EuroQoL-5 dimensions questionnaire
(EuroQol-5D), pre-session with post-session salivary cortisol and alpha-amylase for
the last four AAT sessions, and adherence rates between different elements of the
program. We conducted a randomized, controlled study in a psychiatric care center
in Spain. Twenty-two institutionalized patients with chronic schizophrenia completed
the 6-month rehabilitation program, which included individual psychotherapy, group
therapy, a functional program (intended to improve daily functioning), a community
program (intended to facilitate community reintegration) and a family program. Each
member of the control group (n = 8) participated in one activity from a range of
therapeutic activities that were part of the functional program. In place of this functional
program activity, the AAT-treatment group (n = 14) participated in twice-weekly 1-h
sessions of AAT. All participants received the same weekly total number of hours of
rehabilitation. At the end of the program, both groups (control and AAT-treatment)
showed significant improvements in positive and overall symptomatology, as measured
with PANSS, but only the AAT-treatment group showed a significant improvement in
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negative symptomatology. Adherence to the AAT-treatment was significantly higher than
overall adherence to the control group’s functional rehabilitation activities. Cortisol level
was significantly reduced after participating in an AAT session, which could indicate
that interaction with the therapy dogs reduced stress. In conclusion, the results of this
small-scale RCT suggest that AAT could be considered a useful adjunct to conventional
psychosocial rehabilitation for people with schizophrenia.
Keywords: animal-assisted therapy, psychosocial rehabilitation, adherence to treatment, schizophrenia, PANSS,
EuroQol-5 dimensions, salivary cortisol, salivary alpha-amylase
INTRODUCTION
Interactions with companion animals appear to have positive
effects on physiological, psychological, and social aspects
of human wellbeing (Fine, 2010). Animal assisted therapies
(AAT) seem to produce therapeutic benefits in different
kinds of patients, from those with physical ailments, such as
cardiovascular disease, to those with mental disorders ranging
from dementia to depression (Pedersen et al., 2011) and
schizophrenia (Barak et al., 2001). It has been suggested that
AAT might help to develop the therapeutic relationship between
patients and healthcare professionals, and could improve the
therapeutic atmosphere (Fine, 2010; Julius et al., 2013); animals
in AAT can act as social facilitators, social modulators, and
amplifiers of emotional reactivity (Fine, 2010).
However, scientific evidence for the benefits of AAT is still
very limited (Nimer and Lundahl, 2007; Kamioka et al., 2014),
partially due to intrinsic difficulties of performing research
with AAT (Nimer and Lundahl, 2007; Kamioka et al., 2014).
Typical methodological limitations of AAT include: small sample
size, difficulties of blinding, lack of an adequate control group,
selection bias due to including only participants who like animals,
lack of physiological evaluation, short program duration and
the limited number of professionals and animals that currently
participate in AAT. Some of these limitations are very difficult
to overcome, because of the nature of AAT interventions. For
example, in AAT, it is very difficult to find a comparable
therapeutic activity for the control group, and it is impossible to
blind for the presence of the animal. Since AAT is still considered
an alternative therapeutic approach, very few resources are
dedicated to it within the health system (Kaplan and Sadock,
1989). As a consequence of these limitations it is important
to compile studies with partial evidence for AAT efficacy
and applicability (Fine, 2010) and to improve and standardize
research methodologies (Kamioka et al., 2014).
Recent reviews of AAT research indicate that mental health
disorders are a good target for AAT interventions (Nimer
and Lundahl, 2007; Villalta-Gil and Ochoa, 2007; Rossetti and
King, 2010; Kamioka et al., 2014). Some studies have shown
that AAT programs could benefit patients being treated for
schizophrenia (Kovács et al., 2004, 2006; Nathans-Barel et al.,
2005; Chu et al., 2009). Suggested benefits include effects on self-
esteem, self-determination, positive symptomatology, emotional
symptomatology, anhedonia, and daily functioning (Nathans-
Barel et al., 2005; Villalta-Gil and Ochoa, 2007; Villalta-Gil et al.,
2009; Kamioka et al., 2014).
The aim of this study was to assess the effect of an
AAT program as an adjunct to conventional psychosocial
rehabilitation for people with schizophrenia.
Based on the hypothesis that inclusion of AAT in a
rehabilitation program would have a beneficial effect, our study
had three objectives; to analyze the impact on symptomatology
and quality of life, to evaluate the patient’s experience of the
AAT sessions, and to assess stress relief during the AAT sessions.
For the first objective, the measures used were the Positive
and Negative Syndrome Scale (PANSS; Kay et al., 1989; Peralta
and Cuesta, 1994), and EuroQoL-5 Dimensions questionnaire
(EQ-5D; Bobes et al., 2005). For the second objective, we used
adherence (proportion of programmed sessions that a patient
attended). Adherence was used as an indicator of the relative
appeal of the AAT sessions, by comparing adherence for the AAT
sessions with combined adherence for the functional program
attended by the control group. For the last objective, since stress
management is one of the main objectives for the treatment of
inpatients with mental disorders (Klainin-Yobas et al., 2015), we
evaluated the stress-relieving aspect of the sessions by making
a pre- versus post-session comparison of values for salivary
cortisol and alpha-amylase for the last four AAT sessions. To
our knowledge, previous research on the effects of AAT for
patients with schizophrenia has not included the combination
of these three different types of objectives (and the associated
measures).
Our general objective was to present evidence that was
different and complementary to existing research and to identify
interesting target measures, such as adherence to treatment and
physiological measures, that could be used for future research.
MATERIALS AND METHODS
Study Design
The study was a randomized, controlled trial (RCT).
In this study, primary outcomes for all participants were
changes in symptomatology (measured with PANSS) and
changes in quality of life (measured with EQ-5D). Secondary
outcomes of this study consisted of adherence to AAT sessions
(AAT-treatment group) versus adherence to other activities of
functional rehabilitation (control group), and changes in salivary
cortisol and alpha-amylase during AAT sessions, as a measure of
stress relief (AAT-treatment group only).
Patients were randomly assigned to the control or AAT-
treatment group.
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The laboratory technicians who analyzed the saliva samples
were only given the patients’ ID numbers, and were blinded to
whether patients were in the control or AAT-treatment group.
For practical reasons and for issues relating to the availability of
resources and personnel, the rest of the process of the study could
not be blinded. It was not possible for patients to be blinded to
the presence of dogs, and only one hospital neuropsychologist
was able to participate in the study (in charge of all of the
pre-treatment and post-treatment evaluations of the study, and
follow-up of all of the patients). A single researcher not only
carried out the collection of the data and saliva samples, but also
acted as a guide for the therapy dogs during the AAT sessions.
Sample
The study was conducted in a public psychiatric hospital within
an urban area of Spain. In order to avoid the confounding effects
of environmental variation, only patients from the same unit
were included (MILLE: Long and medium-stay unit). All eligible
patients from the MILLE unit who fulfilled the following criteria
were included:
• Diagnosis of schizophrenia, according to the Revised forth
edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR; American Psychiatric Association,
2000).
• Enrolled in a psychosocial rehabilitation process.
• With a projected minimum hospitalization term of
6 months.
A set of exclusion criteria was also applied, which included:
• Compromised mobility.
• Presence of allergies to animals.
• Rejection of contact with companion animals.
• Confirmed diagnosis of a coagulopathy.
These inclusion and exclusion criteria were adapted from
previous AAT protocols (Barak et al., 2001; Kovács et al., 2004;
Nathans-Barel et al., 2005; Villalta-Gil et al., 2009; Fine, 2010;
Lang et al., 2010). All patients in the unit who met the criteria
were included in the study.
Twenty-four adult patients (Mean age = 47.8 years of age;
SD = 6.7) fulfilled the requirements and were included in the
study. The patients’ mean age at diagnosis of schizophrenia was
20.5 years of age (SD= 5.0). The patients’ mean scores for PANSS
were: 43.8 (SD = 12.3) for General PANSS, 24 (SD = 6.6) for
Negative PANSS and 20.6 (SD = 6.6) for Positive PANSS. The
EQ-5D total score mean was 1.8 (SD = 1.5). See Table 1 for an
overview of all of the characteristics of the sample population.
The 24 patients who met the inclusion criteria were randomly
assigned to three groups, with eight patients in each group (AAT-
treatment groups A and B, and a control group C) (See Figure 1).
Given the length of the study (6 months), a high drop out
rate was expected. Other authors recommend that group size is
kept small for AAT sessions (Kovács et al., 2004; Nathans-Barel
et al., 2005; Chu et al., 2009; Fine, 2010). To comply with this
recommendation, the 16 patients who were to be given AAT were
randomly allocated to one of two small therapy groups (eight
people in each). There were no differences in the characteristics of
these groups, or in the AAT-therapy they received. In the analysis,
data from patients in both therapy groups (A and B) was therefore
combined into a single group.
Five therapy dogs that had previously been assessed and
trained, and had experience of participation in AAT work were
used for the study. There is no official dog therapy certification in
Spain. A thorough physical and behavioral examination of each
dog was performed by a panel of three board-certified specialists
in veterinary behavioral medicine. This examination included
the Ethotest (Lucidi et al., 2005), a test designed to identify
suitable therapy dogs, and the C-BARQ (Hsu and Serpell, 2003),
a questionnaire for measuring behavior and temperament traits
in dogs.
Interventions
The study took place between October 2012 and May 2013.
At the psychiatric hospital where the study was conducted,
the global psychosocial rehabilitation process consisted of five
types of programs: individual psychotherapy, group therapy
program, functional program (to improve daily functioning),
community program (with social reintegration objectives), and
family program. From Monday to Friday every week, all patients
treated in this global psychosocial rehabilitation process had to
participate in all five types of program.
Patients in all groups participated in the same total weekly
number of hours of activity within the psychosocial rehabilitation
process. For the AAT-therapy groups (A and B) the AAT program
was one of these activities. The AAT program consisted of 6-
months of twice-weekly 1-h sessions (Tuesday and Friday), so
that each patient attended a total of 40 AAT sessions (taking into
account public holidays). Control group patients attended the
same number of sessions in the functional program.
The AAT-treatment involved three types of sessions:
(a) Sessions to develop the emotional bond between
participants and dogs: The participants were taught
to handle and take care of the dogs correctly. In this type
of session, concepts of animal welfare and responsible
ownership were explained and practiced.
(b) Sessions involving walking the dogs: During the first half of
the program, the dogs were walked in a large natural park,
so that the patients could learn to walk the dogs in a calm
and controlled manner. For the rest of the program, the
participants walked the dogs in the city, where they could
experience dog-walking in a social context that is typical of
that which is experienced by dog owners.
(c) Sessions to train and play with dogs: Patients learned to
give instructions to the dogs and train them using positive
reinforcement training techniques.
During an AAT session 4 of the 5 therapy dogs were always
present to interact with the patients. At the beginning of each
session, participants were asked to work in pairs. Each working
pair was assigned a dog, which they worked with for the
remaining hour of the session. During the program there was a
rotation between the three types of sessions (emotional bonding,
dog walking, and dog training with play).
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Each patient in the control group was assigned to a single
activity from the functional program on the basis of their
therapist’s criteria, but taking into account the individual’s
preferences. The choice was between art therapy, group
sports (football or basketball), dynamic psycho-stimulation, and
gymnastics. These activities were organized so that they closely
matched certain important characteristics of the AAT program:
• They were conducted outside the hospital unit where the
patients were resident.
• They all involved a similar element of group work.
• Group sizes were small (similar to the AAT sessions).
• Patients were accompanied and supervised off-site by a
mental health professional (nurse or similar).
• The activities continued throughout the period of trial (they
were unaffected by season).
• The sessions were twice-weekly and of 1-h duration.
The difference between functional program activities and the
AAT sessions was, as far as was possible, restricted to content.
Instruments
To compare evolution in psychiatric symptoms between AAT-
treatment and control patients during the 6-month duration of
the program, we used the previously validated Spanish version
of the Positive and Negative Syndrome Scale (PANSS; Kay
et al., 1989). PANSS has been found to be a reasonably valid
psychometric tool for people with schizophrenia (Kay et al., 1989;
Peralta and Cuesta, 1994), and is one of the most widely used
tools for the assessment of therapeutic results in schizophrenia
treatment. PANSS was administered to all patients during
individualized interviews with the hospital neuropsychologist. It
was completed for each patient several times in the month before
the study started, during the program and in the month after the
end of the program.
The same interview approach was used to assess quality of life,
using the EQ-5D (Bobes et al., 2005). The EQ-5D has been found
to be reasonably valid for use in people with schizophrenia (König
et al., 2007) and is a standard assessment instrument used in this
hospital. The neuropsychologist completed the EQ-5D twice with
each patient, in the month before the study started and in the
month after the end of the program.
Individual attendance at sessions of AAT and the functional
program was recorded. Adherence was calculated as the
proportion of programmed sessions that a patient attended
during the 6-month program period, expressed as a percentage.
In order to study the physiological effects of contact with the
dogs during an AAT session, pre- and post-session saliva samples
were collected for the last four AAT sessions of the program.
Salivary alpha-amylase (sAA) and cortisol were measured. As
a biomarker of psychosocial stress, salivary alpha-amylase can
be considered to be a measure of the level of activation of the
sympathetic nervous system (SNS; Rohleder et al., 2006; Holt-
Lunstad et al., 2008). Salivary cortisol is an indicator of the
state of the hypothalamic–pituitary–adrenal (HPA) axis and is a
general physiological biomarker of stress (Fortunato et al., 2008;
Holt-Lunstad et al., 2008). Saliva samples were collected using a
commercial saliva collection kit (Salivettes R©, Sarstedt), with the
Salivette remaining in the patient’s mouth for 1 min per sample.
Two samples were collected from each patient at each of the four
sessions; one was collected 30 min before the AAT session and the
other 10 min after the AAT session had finished. Saliva samples
were stored in a dry-ice cooled mobile fridge, in which they were
delivered to the laboratory to be processed and frozen to −80◦C
for later testing. The maximum pre-freezing storage time was 4 h.
After the study was completed, all saliva samples were thawed and
analyzed. Cortisol was extracted and analyzed using a commercial
immunoassay (Siemens IMMULITE 2000, Siemens Healthcare
Diagnostics. Deerfield, IL, USA; Owen and Roberts, 2011; Tecles
et al., 2014), and alpha-amylase was analyzed using a commercial
spectrophotometric assay (Olympus AU2700. Olympus America
Inc. Center Valley, PA, USA; Tecles et al., 2014).
Statistical Analysis
We analyzed data from all the participants who completed the 6-
month period of the study (N = 22). In the present study, patients
were included in the analysis regardless of their level of adherence
to their medication regime or any of the five elements of the
psychosocial rehabilitation process, and adherence to the AAT
program was a main outcome measure. As a result, the present
study does not comply with the requirements for a ‘per protocol’
analysis, in which patients would be excluded for any deviation
from treatment. However, because we excluded two patients who
did not complete the study we also did not carry out an ‘intention
to treat’ analysis, and so our protocol could be described as a
‘modified intention to treat.’
Between-group (control and AAT-treatment) contrasts of
PANSS and EQ-5D scores were analyzed using Statistica 10 and
GraphPad Prism 6. Data was tested for normality using the
Shapiro–Wilk test; parametric data was tested using a t-test,
and non-parametric data was tested using the Mann–Whitney
U (for unpaired data) or Wilcoxon test (for paired data). For
dichotomous variables (patient sex), a chi-square test was used
to compare proportions between groups. Multiple comparisons
were made in the EQ-5D analysis, so the Bonferroni correction
was used to adjust the value of p that was accepted for significance
(for example, for 20 comparisons, p= 0.05/20= 0.0025).
Pre-program PANSS and EQ-5D scores were compared with
post-program scores, for the AAT-treatment and control groups
separately. After checking normality of data (with the Shapiro–
Wilk test), a paired-samples t-test was used with parametric
data and the Wilcoxon test was used with non-parametric
data.
Adherence to treatment data was checked for normality using
the Shapiro–Wilk test. An unpaired t-test (for parametric data)
or Mann–Whitney U (for non-parametric data) was used to
compare adherence levels between the AAT-treatment group and
either overall compliance or compliance for individual activities
within the functional programs (control group).
A paired t-test was used to compare pre- with post-session
levels of cortisol and alpha-amylase in the AAT-treatment group
(data had been found to be normally distributed using the
Shapiro–Wilk test).
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Ethics
The Clinical Research Ethics Committee of the Hospital del
Mar Medical Research Institute (IMIM) approved the clinical-
protocol, patient management, and participation of the patients.
The Department of Agriculture and Natural Environment of
the Catalonia Government approved the animal management
protocol for this study. All dogs that participated in the
project were given a thorough medical, behavioral, and welfare
assessment before, during, and after the AAT program.
All patients who were eligible for the study received
documentation that outlined the study, and they signed an
informed consent form. They were able to withdraw from the
study at any time.
Animal assisted therapy technicians signed an informed
consent form that detailed their responsibilities (confidentiality
and conformity) within the project.
Spanish law 15/99 (regarding personal data protection) was
applied to all data collection.
RESULTS
Sample Characteristics
There were no differences between control and AAT-treatment
groups with respect to sex [Chi-square test; χ2(1)= 0.40], age or
initial scores of PANSS and EQ-5D (Mann–Whitney U; p< 0.05;
See Table 2 for full details).
During the program, two patients within the AAT-treatment
group withdrew from the study. One patient was discharged from
the hospital before the end of the AAT program. The other patient
exhibited behaviors that threatened to compromise the welfare of
the therapy dogs, and therefore stopped participating in the AAT
activity (See Figure 1).
Schizophrenic Symptomatology (PANSS)
At the end of the program, no significant differences were found
between control and AAT-treatment groups (Mann–Whitney U
test, p < 0.05) with respect to final PANSS or change in PANSS
(see Table 3 for full details). However, there were significant
differences in PANSS pre-treatment and post-treatment scores in
both control and AAT-treatment groups (t-test; p < 0.05). In the
AAT-treatment group, scores for all PANSS subscales (positive,
negative, and general) were significantly lower after the AAT
program (t-test; p < 0.05). In the control group, only positive
and general PANSS scores showed a significant decrease after
treatment (t-test; p< 0.05). For full details, see Table 4.
Quality of Life (EQ-5D)
No significant difference was found between AAT-treatment
and Control groups (Mann–Whitney U test; p < 0.0025 after
Bonferroni correction). In addition, almost none of the EQ-
5D items were significantly different after treatment (Wilcoxon
test; p < 0.05; Table 5). Only the score for the general health
item (compared with 12 months before) of the EQ-5D was
significantly lower after the program in the AAT-treatment group
(Wilcoxon test; p < 0.05). For this item, low scores indicate
higher health status, meaning that AAT-treatment group patients
perceived themselves to be in a better state of health after the
program. However, after applying a Bonferroni correction none
of the results of EQ-5D was significant different after treatment
(for eight comparisons, p= 0.05/8= 0.0625).
Adherence to Treatment
Although patients were encouraged, and expected, to attend all
scheduled activities, attendance was entirely voluntary. In the
AAT-treatment group, there was an overall 92.9% (SD = 4.7)
adherence to treatment for the AAT sessions. The majority
of absences from the AAT sessions were due to family or
health issues. Only once did a patient not want to attend an
AAT session. In the control group, there was an overall 61.2%
(SD = 24.8) adherence to treatment for the assigned activity
from the functional program. This higher level of adherence
to the AAT sessions, compared with overall adherence to
the functional activities, was significant [t-test: t(20) = 4.7;
TABLE 2 | Initial scores of PANSS and EQ-5D of the analyzed patients of this study.
Mean (SD)
INITIAL SCORES Treatment (N = 14) Control (N = 8) U Z adjusted 2 sided exact p∗
AGE 48.9 (6.7) 46.7 (7.3) 40.5 1.02 0.29
PANSS positive 18.9 (6.0) 20.7 (5.7) 46 −0.64 0.52
PANSS negative 25.3 (7.5) 21.70 (4.5) 39.5 1.09 0.26
PANSS general 44.3 (12.3) 42.6 (13.7) 51.5 −0.27 0.76
EQ-5D Total score 1.9 (1.8) 1.5 (1.3) 49.5 0.42 0.66
EQ-5D- Health Today (0–100) 80.7 (24.9) 78.7 (18.3) 42 0.94 0.36
EQ-5D- F1 Mobility 0.1 (0.3) 0.1 (0.3) 53 −0.34 0.86
EQ-5D- F2 Personal Care 0.1 (0.4) ∗∗ 48 1.02 0.61
EQ-5D- F3 Daily Activities 0.1 (0.3) 0.2 (0.7) 52.5 −0.41 0.81
EQ-5D- F4 Pain/Discomfort 0.4 (0.6) 0.5 (0.5) 50 −0.43 0.71
EQ-5D- F6 Health State 12 m 0.4 (0.6) 0.4 (0.7) 51.5 0.33 0.76
Comparison between control and treatment group. ∗Mann–Whitney U Test. Tests are significant at p < 0.05. No significant results were found. ∗∗Data for the initial item
EQ-5D F5 Anxiety was not included because some patients were not able to fully understand the meaning of this item.
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TABLE 3 | Differences between control and treatment groups with respect to final PANSS (after 6 months of treatment) or change in PANSS.
Mean (SD)
Treatment (N = 14) Control (N = 8) U Z adjusted 2 sided exact p∗
PANSS positive score FINAL 13.6 (3.8) 12.9 (5.2) 52 0.24 0.81
PANSS positive change 5.3 (4.8) 7.9 (4.3) 38.5 1.16 0.23
PANSS negative score FINAL 19.6(7.0) 19.9 (5.4) 55 −0.03 0.97
PANSS negative change −11.7 (7.4) −8.9 (4.8) 41 −0.99 0.33
PANSS general score FINAL 34.3 (8.6) 30.0 (6.0) 37 1.26 0.21
PANSS general score change 5.6 (8.9) 1.9 (3.4) 45 0.71 0.48
∗Mann–Whitney U Test. Tests are significant at p < 0.05. No significant results were found.
TABLE 4 | Differences in PANSS pre-treatment and post-treatment scores in both control and treatment (AAT) groups.
Group Variable Number of pairs (pre vs. post) Mean (SD) t (df) p-value
Control PANSS positive 8 7.87 (4.29) t(7) = 5.19 0.001∗
Control PANSS negative 8 1.87 (3.44) t(7) = 1.54 0.167
Control PANSS general 8 12.63 (13.57) t(7) = 2.63 0.033∗
AAT PANSS positive 14 5.28 (4.78) t(13) = 4.13 0.001∗
AAT PANSS negative 14 5.64 (8.19) t(13) = 2.57 0.022∗
AAT PANSS general 14 10.00 (8.70) t(13) = 4.30 0.001∗
∗t-test (considered significant at p < 0.05).
TABLE 5 | Differences in EQ-5D pre-treatment and post-treatment scores in both control and treatment groups.
Group Variable Number of pairs Type of test t (df) or W p-value
Control EQ-5D Total score 8 T t(7) = 1.8 0.11
Control EQ-5D Health today 12 m 8 W W = 9 0.53
Control EQ-5D Mobility 8 W W = 0 >0.99
Control EQ-5D Pain/discomfort 8 W W = 3 0.50
Control EQ-5D Health State today 8 W W = 0 >0.99
Control EQ-5D Anxiety/Depression 8 W W = −3 0.50
Control EQ-5D Daily Activities 8 W W = −1 >0.99
Control EQ-5D Personal Care 8 ∗∗ ∗∗ ∗∗
Treatment EQ-5D Total score 14 W W = −3 0.91
Treatment EQ-5D Health today
12 m
14 W W = 37 0.03∗
Treatment EQ-5D Mobility 14 ∗∗ ∗∗ ∗∗
Treatment EQ-5D Pain/discomfort 14 W W = −3 0.76
Treatment EQ-5D Health State today 14 W W = 0 >0.99
Treatment EQ-5D Anxiety/Depression 14 W W = 0 0.34
Treatment EQ-5D Daily Activities 14 W W = −10 0.07
Treatment EQ-5D Personal Care 14 W W = 3 0.34
(T) t-test (data passed normality test). (W) Wilcoxon test (data did not pass normality test). ∗Tests are significant at p < 0.05 (If apply Bonferroni correction:
p = 0.05/8 = 0.00625). ∗∗Could not calculate because the values to compare were the same.
p = 0.0001]. We could only compare adherence to AAT-
treatment with specific functional program activities for which
the number of attending patients was large enough to justify
a statistical test (art therapy and gymnastics). AAT showed
significantly better adherence than art therapy (Mann–Whitney
U test; U = 2; p = 0.01) and gymnastics therapy (Mann–
Whitney U test; U = 2; p = 0.01). All detailed data on
adherence to treatment are presented in Tables 6 and 7 and see
Figure 2.
Salivary Cortisol and Alpha-Amylase
We collected 61 pre-session and 60 post-session saliva samples
from the AAT-treatment group. However, some of the saliva
samples were too small for analysis and were discarded.
Cortisol analysis was performed with 48 matched pairs
of samples (matching every corresponding pre-session and
post-session sample for each session for which sufficient
sample was available). There was a significant decrease in
cortisol after participation in an AAT session (Wilcoxon Test;
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TABLE 6 | Patients’ adherence to treatment.
Patient ID Group Number of programmed sessions Number of attended sessions Percentage of adherence
1 Treatment 40 38 95
2 Treatment 40 37 92.5
3 Treatment 40 39 97.5
4 Treatment 40 40 100
5 Treatment 40 37 92.5
6 Treatment 40 34 85
7 Treatment 40 39 97.5
8 Treatment 40 36 90
9 Treatment 40 37 92.5
10 Treatment 40 38 95
11 Treatment 40 37 92.5
12 Treatment 40 34 85
13 Treatment 40 39 97.5
14 Treatment 40 35 87.5
15 Control 28 16 57.1
16 Control 28 6 21.4
17 Control 28 13 46.4
18 Control 21 18 85.7
19 Control 28 25 89.3
20 Control 28 18 64.3
21 Control 56 22 39.3
22 Control 56 48 85.7
MEAN(SD) All patients 37.9 (8.4) 31.1 (10.1) 81.3 (21.5)
Treatment group 40.0 (0.0) 37.1 (1.9) 92.9 (4.7)
Control group 34.1 (13.7) 20.8 (12.4) 61.2 (24.8)
TABLE 7 | Differences in adherence to treatment between AAT and other types of functional rehabilitation interventions.
Type of compared functional intervention Number of participants in the control group Type of test t (df) or U p
AAT vs. Art therapy 3 U U = 2 0.010∗
AAT vs. Gymnastics 3 U U = 2 0.010∗
AAT vs. Psychodynamic therapy 1 U ∗∗ ∗∗
AAT vs. Group sport 1 U ∗∗ ∗∗
AAT vs. all other 8 T t(20) = 4.7 0.001∗
(T) t-test (data passed normality test). (U) Mann–Whitney U Test (data did not pass normality test). ∗Tests are considered significant at p < 0.05. ∗∗Not possible to calculate
because not enough values in the control type of intervention.
p < 0.05. Pair-matching was confirmed using the Spearman
test; p < 0.05). Fifty pairs of matching samples were used
to measure the effect of the intervention on salivary alpha-
amylase. sAA was increased after the AAT sessions, but
the difference was not quite significant (Wilcoxon Test;
p= 0.059. Pair-matching was confirmed using the Spearman test;
p< 0.0001).
DISCUSSION
In terms of age and gender, our sample of patients was
consistent with the general population of people with
schizophrenia, as well as the population of institutionalized
people with schizophrenia (Jablensky, 2000; Uggerby
et al., 2011). All participants were receiving at least one
psychotropic drug, as is common in people treated for
this condition (Jablensky, 2000; Uggerby et al., 2011).
Our results could therefore be relevant to other similar
institutions that are considering the implementation of an AAT
program.
With regard to population size, our study was comparable
with similar studies that have investigated the effect of AAT
in the treatment of schizophrenia, suggesting some common
methodological limitations (Barak et al., 2001; Nathans-Barel
et al., 2005; Kovács et al., 2006; Berget, 2008; Chu et al.,
2009; Villalta-Gil et al., 2009). Apart from the constraint of
working with a limited total population of patients within a
single hospital unit, and the application of exclusion/inclusion
criteria, it should be remembered that AAT has to be
conducted in small groups for practical reasons such as the
need for proper supervision and a high animal-to-patient ratio
(Fine, 2010).
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FIGURE 1 | Shows the modified CONSORT flow diagram for individual RCTs of non-pharmacologic treatment (Boutron et al., 2008; Schulz et al.,
2010) applied to this study.
One patient withdrew from the study due to the risk of harm
to the therapy dogs. This kind of problem should have been
anticipated and taken into account within the exclusion criteria.
This should be considered in future studies. Another patient
withdrew very early in the study (week 3), and prior to the
collection of any outcome data. The recommended approach
for superiority studies is an intention to treat analysis, whereby
all patients included in the randomization are included in the
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analysis, and by deviating from this approach in our study
we risk an overestimation of the treatment effect (Armijo-
Olivo and Magee, 2009). So, whilst the results are interesting
and point to a potential effect of treatment, they cannot
be relied upon as general evidence of efficacy in a clinical
population.
People with a diagnosis of chronic schizophrenia who live
in institutionalized settings have very low levels of social
functioning and social activity (Kovács et al., 2004). Individual
or combined measures of symptomatology, quality of life and
adherence to treatment are commonly used to assess the
efficacy of a psychosocial rehabilitation process for patients
with schizophrenia (Wilson-d’Almeida et al., 2013), but not
together in the same study. By including these measures and
adding an assessment of salivary cortisol and alpha-amylase, our
study provides an interesting insight into the use of combined
measures.
In terms of symptomatology, in the AAT-treatment group
we observed an improvement in negative symptoms of
schizophrenia like apathy, asociality, anhedonia and alogia,
that could be partially explained by the regular interaction
between patients and animals. Previous work suggests that
AAT programs may be effective in the control of negative
symptoms of schizophrenia (Barker and Dawson, 1998; Barak
et al., 2001; Kovács et al., 2004; Nathans-Barel et al., 2005).
Therapy dogs have been described as social catalysts or mediators
of interactions between patients and between patients and
their therapists, and these benefits could be extended outside
the AAT sessions (Fine, 2010). Since negative symptoms
of schizophrenia are relatively insensitive to pharmacological
therapies and are associated with a chronic course and high
levels of social disability, it is very important to find effective
alternative interventions that can be added to standard treatment
protocols (Hammer et al., 1995; Liddle, 2000; Gråwe and
Levander, 2001). The beneficial effects of AAT on negative
symptoms of schizophrenia is therefore worthy of further
investigation.
The trend toward an increase in alpha-amylase combined with
the significant decrease in cortisol after the AAT sessions suggests
that the interaction patients had with the dogs was perceived to be
not only engaging, but also relaxing. Increases in alpha-amylase
and the activation of the SNS can occur in positive emotional
states (Fortunato et al., 2008; Payne et al., 2014), and recent
research indicates that people with schizophrenia may experience
a dysregulation of SNS tone (Monteleone et al., 2015).
The lack of significance for the change in salivary alpha-
amylase could be due to the absence of an effect, but also due to
the small population size and the small number of collected saliva
samples (saliva was only collected for the last four AAT sessions,
sample collection was not always successful, and approximately
17% of collected samples had to be rejected due to inadequate
sample volume for analysis).
Regarding stress and cortisol levels, previous research has
found decreases in salivary cortisol during AAT sessions in other
types of patients, such as autistic children (Viau et al., 2010)
and insecure attached males (Beetz et al., 2012a). In a previous
study with people being treated for schizophrenia, cortisol levels
FIGURE 2 | Differences between AAT and other functional
rehabilitation interventions.
were not been found to change after interaction with animals
(Nepps et al., 2014). However, in comparison to our study, the
AAT protocol for that study did not include repeated sessions
for each patient and the ratio of dogs per patient was lower.
Long-term and dose effects of AAT on stress levels of patients
with schizophrenia still need to be studied. Future studies could
take advantage of our experience by extending the measurement
of salivary cortisol to all AAT sessions within a program, and
a control group, while also looking for long-term and dose
effects.
There were some difficulties in collecting saliva samples
in this study, both in terms of quantity and quality of
saliva. The pharmaceutical treatment of schizophrenia involves
drugs that suppress salivation, and as a consequence of their
symptomatology, many people with schizophrenia are smokers
(Rae et al., 2014). Smoking increases cortisol and decreases alpha-
amylase (Granger et al., 2007a), so this could be a confounding
factor. Future studies should include data on patients’ smoking
level, particularly when comparing saliva measures between
groups, as between group matching could be important. In
addition, personal hygiene and dental care seems to be poor in
many people with schizophrenia (Velligan et al., 1997), and the
presence of impurities in saliva samples could interfere with the
reliability of the measurements (Granger et al., 2007b). Ideally,
a patient should have rinsed his or her mouth with water some
minutes before saliva collection, but due to a lack of patient
cooperation this was rarely possible. Future research should try
to extend and optimize saliva sample extraction and analysis, as it
seems cortisol and alpha-amylase could be good markers of AAT
effects in people being treated for schizophrenia.
Frontiers in Psychology | www.frontiersin.org 10 May 2016 | Volume 7 | Article 631
fpsyg-07-00631 May 3, 2016 Time: 14:17 # 11
Calvo et al. AAT for People with Schizophrenia
Quality of life measurements did not differ between pre-
treatment and post-treatment conditions in either of the two
groups. Improvement in symptomatology is not always related to
improvement in quality of life in people with schizophrenia as the
latter can be affected by other factors such us the level of insight
(Wilson-d’Almeida et al., 2013; Hayhurst et al., 2014; Margariti
et al., 2015). Previous research has shown that even patients with
schizophrenia who are undergoing treatment can experience a
progressive decline in their quality of life (Medici et al., 2015).
Therefore, a lack of decline in overall quality of life measurements
could be interpreted to be a benefit of psychosocial rehabilitation,
particularly in chronic patients. Future research could focus on
specific domains of quality of life where AAT seems to have a
direct effect, such as anxiety and depression (Barker and Dawson,
1998) and social relationships (Villalta-Gil et al., 2009).
In the present study, mean adherence to the alternative
functional rehabilitation interventions (art therapy, group sports,
dynamic psycho-stimulation, or gymnastics) was lower in the
control group than the AAT-treatment. Previously reported
adherence rates to therapeutic sport programs for people being
treated for schizophrenia range from 50 to 82% (Beebe et al.,
2005; Warren et al., 2011). In the present study, there were
intrinsic differences between the activities included in the
functional program, but they all shared certain features, such as
frequency, duration, and being conducted outside the hospital.
Although the added value of AAT sessions in terms of adherence
could be due to a novelty effect, attendance to sessions did
not decline during the program. Information about adherence
is rarely reported in AAT research, but it could be a very
useful indicator in the context of psychosocial rehabilitation, and
deserves further research (Kamioka et al., 2014).
Another factor that could be of importance in adherence to
ATT is the human–dog relationship (Nagasawa et al., 2015).
An initial bond may be quickly established between a person
and a dog, and this bond has a strongly emotional element
(Dwyer et al., 2006; Fine, 2010; Beetz et al., 2012b), that leads to
the development of attachment to the dog (Zasloff, 1996). This
attachment could contribute to a person’s sustained interest in
attending AAT sessions, but could potentially lead to problems
when the human–animal bond is disrupted at the end of the
program. Further research could monitor the development of the
patient–dog bond during an AAT program, and the effects of
ending such programs.
Taken together, the various significant results reported in this
study (reduction of negative symptomatology, high adherence to
the AAT program, and cortisol reduction after AAT sessions)
could be explained by the biology of human–animal interactions
(Beetz et al., 2012b; Nagasawa et al., 2015). When a person has
a enjoyable contact with a dog there is a release of oxytocin,
dopamine, and endorphins, as well as a decrease in cortisol (Beetz
et al., 2012a,b; Julius et al., 2013). This overall reaction seems
to enhance pro-social behavior and decrease anxiety and stress,
mainly via the hypothalamic-pituitary axis (HPA; Neumann et al.,
2000). Oxytocin administration has previously been proposed
as a treatment for psychiatric patients because of its broad
pro-social effects on behavior and cognition (Zik and Roberts,
2014). Through the release of oxytocin, positive contact with
dogs could produce such psychosocial and psychophysiological
benefits. Future research in AAT might also try to study changes
in oxytocin levels of people being treated for schizophrenia
during contact with animals.
The results of our study raise some questions that could
be addressed in future work. Adherence to treatment is a
significant problem, especially in lengthy rehabilitation programs
with challenging patients. It would be interesting to investigate
whether the high level of adherence to AAT that we observed is
replicated in other therapeutic situations, and whether adherence
really is different from other closely matched activities. It is
possible that the mere presence of a dog in any type of therapy
session could improve adherence, especially if the patient has
developed a relationship with the dog during AAT, and this
effect should be investigated. In all rehabilitation programs
resources are limited and the inclusion of AAT could represent
an opportunity cost by displacing other activities. It is therefore
important to find out whether patients who have participated in
AAT go on to experience significant long-term benefits after the
rehabilitation program has concluded, compared with patients
who have been involved in other activities.
CONCLUSION
Animal assisted therapy seems to be a worthwhile adjunct
therapeutic approach for people being treated for schizophrenia
in a conventional psychosocial rehabilitation process, with
potential positive outcomes in symptomatology, adherence to
AAT program, and stress reduction during AAT sessions.
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